Life Science Investing PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights
Life Science Investing PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
Life Science Investing PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Life Science Investing PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
Homerun Resources Inc. Receives Conditional Approval from the TSXV for $6 Million Financing with Institutional Investor
Silver Dollar Samples Up to 2,753 g/t AgEq in Underground Sampling Campaign at its La Joya Silver Project
